

Grifols SA (GRFS) Government Trades - Latest Congressional Stock Transactions
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.
top performing (GRFS) trades

Recent Grifols (GRFS) Trades by Congress Members
See the most up-to-date Grifols trades disclosed by US lawmakers, including purchase and sale amounts, transaction dates, and reporting details. View the most recent Grifols trades made by congress members.
![]() Daniel GoldmanHouse (D-NY) | $1K - $15K | stock | Sale | Mar 31, 2023 | House | |
![]() Daniel GoldmanHouse (D-NY) | $1K - $15K | stock | Purchase | Feb 27, 2023 | House |